Posted by Maria3667 on July 28, 2007, at 12:54:31
In reply to Re: When is Gepirone approval due?, posted by Cecilia on July 26, 2007, at 22:41:20
Hi Cecilia,
Know what you mean about being dissapointed.
Side effects have to be prooven by a larger audience than the participants in the clinical trials, in my opinion.
I know Gepirone is structurally related to Buspar, but from what I've read, because of a slight molecular difference it has a completely new mode of action. True or false? May be it's a fairy tale from a spin dr for the company? I'll gladly volunteer as a guinea pig and proove them right/wrong!
By the way, Reboxetine & Cymbalta are available in my country. However, I don't think Ensam has made it through yet. A friend of mine is eagerly awaiting the EMA's (the 'FDA' for the European Union) approval for Agomelatine, also a novel AD working on an an 5-HT2b antagonist, 5-HT2c antagonist, melatonin M1 receptor agonist and melatonin M2 receptor agonist. Agomelatonine is reported to have few or zero sexual side effects.
Keeping me of the streets this hobby of mine, tracking down new meds!
Cheers,
Maria> I hope your hopefulness proves right, Maria. We'll see. Some of the meds that people were eagerly awaiting on Psychobabble, like Reboxetine, disappeared, never to be heard of again. Others, Cymbalta and Emsam, eventually did appear, and in my case, after the long waits, proved to have no beneficial effects and even worse side effects than the old drugs. From what I'm read, Gepirone is pretty similar to Buspar, which certainly was no miracle drug (for me) but most likely I'll give it a try if it actually is approved. There's always that one in a million chance I suppose. Cecilia
poster:Maria3667
thread:771351
URL: http://www.dr-bob.org/babble/20070719/msgs/772547.html